SARS-CoV-2 Antigen Rapid Test
Introducing the SARS-CoV-2 Rapid Antigen Test
The Flowflex SARS-CoV-2 Antigen Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection of the nucleocapsid
protein antigen from SARS-CoV-2 in nasal swab specimens directly from individuals who are suspected of an active COVID-19 infection.
What is the Test?
- A rapid test for the detection of SARS-CoV-2 nucleocapsid antigens in anterior nasal swab specimens.
* For general use. Self testing.
What is the Disease?
- SARS-CoV-2 belongs to the Coronaviridae family and is closely related to the SARS coronavirus that appeared in 2002/2003. The virus was first identified in humans in Wuhan, China, at the end of 2019, and is transmissible from person to person.
- The main route of transmission is droplet infection, but infections via aerosols and smear have also been described.
- The incubation period is usually three to seven days, up to a maximum of fourteen days. SARS-CoV-2 infected patients are often asymptomatic or experience only mild symptoms such as a dry cough, fever, and shortness of breath.
- Some of the infected persons develop a severe pneumonia, which can lead to death.
Key Features
- Supplied in a single pack
- Cassette Format
- Detects the nucleocapsid protein antigen from SARS-CoV-2
- Nasal Specimen sample. Anterior Nares Only Test (2-4cm inside the nostril)
- Results in 15 minutes
- CE Marked for Self Test
- Used by NHS track and trace as home test
Best In Class Performance
Performance
- Relative Sensitivity: 97.1% (83.8%-99.9%)*
- Relative Specificity: 99.6% (97.7%-99.9%)*
- Accuracy: 99.3% (97.5%-99.9%)*
*95% Confidence Intervals
About Katalyst Laboratories
Katalyst Laboratories is a leading distributor of diagnostics testing equipment, PCR assays and LFT tests.
Fully supported by training, support and regular bio surveillance updates.
Katalyst was a leading Covid testing lab during the pandemic, achieving ISO 15189 and ISO 22870, invited by the UK Government as the first laboratory to participate in Heathrow testing trials in July 2020.
CONTACT US
We’d love to hear from you.
Please send a brief summary of your project and requirements and we’ll be in touch to discuss further.